Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $294000.0.

  • Vistagen Therapeutics' Change in Accured Expenses fell 8513.65% to $294000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 million, marking a year-over-year decrease of 1327.01%. This contributed to the annual value of $5.7 million for FY2025, which is 98831.42% up from last year.
  • Vistagen Therapeutics' Change in Accured Expenses amounted to $294000.0 in Q4 2025, which was down 8513.65% from $3.2 million recorded in Q3 2025.
  • Vistagen Therapeutics' Change in Accured Expenses' 5-year high stood at $3.7 million during Q3 2021, with a 5-year trough of -$2.4 million in Q2 2025.
  • Moreover, its 5-year median value for Change in Accured Expenses was $434750.0 (2023), whereas its average is $560480.0.
  • Within the past 5 years, the most significant YoY rise in Vistagen Therapeutics' Change in Accured Expenses was 67479.42% (2021), while the steepest drop was 177546.47% (2021).
  • Quarter analysis of 5 years shows Vistagen Therapeutics' Change in Accured Expenses stood at -$1.5 million in 2021, then grew by 3.38% to -$1.5 million in 2022, then skyrocketed by 118.4% to $269000.0 in 2023, then soared by 635.32% to $2.0 million in 2024, then plummeted by 85.14% to $294000.0 in 2025.
  • Its Change in Accured Expenses was $294000.0 in Q4 2025, compared to $3.2 million in Q3 2025 and -$2.4 million in Q2 2025.